

# Drug investment and disinvestment: methods, outcomes, and challenges

Presenter: Dr Lan Gao  
Research Fellow of Health Economics  
University of Deakin, Australia

Feng Xie, PhD  
Professor of Health Economics  
Department of Health Research Methods, Evidence and Impact (formerly  
Clinical Epidemiology and Biostatistics) McMaster University



## Disclosures

- **This presentation does not necessarily reflect the views of any of the following institutions:**


Canadian Institutes for Health Research

McMaster University

St. Joseph's Healthcare Hamilton


EuroQol Research Foundation

# Why



Source: OECD (2017), Pharmaceutical spending (indicator). doi: 10.1787/998feb6-en (Accessed on 08 November 2017)


## Increasing efficiency $\neq$ reducing cost




# A global health care challenge

Controlling costs, without compromising health and quality of health care


## Drug life cycle




# Current drug list




# New drugs to be covered





## Disinvestment implemented



## Improving in efficiency



# New drug list



## Initiation

- Drug manufacturers (passive)
- Policy makers (active)

## Identification

- Systematic approach
  - New evidence
  - Patent expiry/generic drugs
  - Clinical practice pattern variation
- Request-driven initiation (passive)
  - Commercial factors
  - Safety

# Identification

- Active investment and disinvestment system
  - First time, all drugs/phase-in
  - Post-marketing surveillance
  - Evidence update
- Passive investment and disinvestment system
- Target
  - Clinically ineffective
  - Safety issue
  - Little or no health gain for the cost
  - Cheaper generic drugs available

# Evaluation

- Efficacy and Safety
- Effectiveness
- Cost Effectiveness




# Implementation

**General** Encouraging generic prescribing

**Targeting** Restricting to specific groups

## (Re)assessment System



## Challenges

- Identifiable candidates for disinvestment
- Experts more conservative when saying NO
  - Older treatments with no contemporary evidence
  - No evidence vs evidence of no effect or of harm
- Resistance from stakeholders
- National database to track the usage
- Short term investment with saving in the long term

## Contact Information

For more information, please direct to:

[fengxie@mcmaster.ca](mailto:fengxie@mcmaster.ca)

For more information about **Program for Health Economics and Outcome Measures (PHENOM)**

please visit: [www.phenomresearch.ca](http://www.phenomresearch.ca)